| 8.73 0.03 (0.34%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 22.47 | 1-year : | 31.52 |
| Resists | First : | 19.24 | Second : | 26.98 |
| Pivot price | 8.92  |
|||
| Supports | First : | 6.71 | Second : | 5.58 |
| MAs | MA(5) : | 8.56 |
MA(20) : | 9.21 |
| MA(100) : | 14.72 |
MA(250) : | 126.17 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 14 |
D(3) : | 9.9 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 896 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CERO ] has closed above bottom band by 37.2%. Bollinger Bands are 85.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.85 - 8.89 | 8.89 - 8.93 |
| Low: | 8.3 - 8.35 | 8.35 - 8.39 |
| Close: | 8.65 - 8.73 | 8.73 - 8.8 |
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Fri, 18 Jul 2025
Cero Therapeutics completes additional sale of Series D preferred stock - Investing.com
Fri, 18 Jul 2025
CERo Therapeutics Completes Series D Stock Sale - TipRanks
Fri, 18 Jul 2025
What analysts say about CERo Therapeutics Holdings Inc. stock - Consistently superior profits - Jammu Links News
Fri, 18 Jul 2025
What analysts say about CERo Therapeutics Holdings Inc. stock - Massive wealth growth - Jammu Links News
Tue, 15 Jul 2025
What makes CERo Therapeutics Holdings Inc. stock price move sharply - Free Popular Stock Recommendations - beatles.ru
Mon, 14 Jul 2025
Cero Therapeutics enters $17.5 million equity purchase agreement with investor By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8.2 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | -582.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -10.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -31.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.82 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|